Positive Initial Interim Safety and Efficacy Results Announced from RAMP 205 Trial of Avutometinib, Defactinib, Gemcitabine and Nab-paclitaxel combo in 1L Metastatic Pancreatic Cancer May 29, 2024
Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer May 29, 2024
Ph 2/3 Trial of Surufatinib + Camrelizumab combo for 1L Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui Initiated May 21, 2024
Paediatric Investigation Plan Waiver Received from the European Medicines Agency for Certepetide in Pancreatic Cancer May 21, 2024
U.S. FDA Accepts and grants Priority Review of BLA for Zeno for the Treatment of NRG1+ NSCLC and PDAC May 15, 2024
First Dose Level found to be Generally Well-Tolerated in Ph 1b/2 Study of Ampligen and Imfinzi Combination for Late-Stage Pancreatic Cancer May 1, 2024
FDA approves Lutathera® for pediatric patients with gastroenteropancreatic neuroendocrine tumors May 1, 2024
Positive Interim Data Announced from Randomized Ph 2 Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer April 8, 2024
Positive Findings announced from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research March 26, 2024
PT886 granted Fast Track designation for the treatment of patients with metastatic claudin 18.2-positive pancreatic adenocarcinoma by the FDA March 26, 2024
DURIPANC Ph 1b/2 clinical trial of Ampligen with Imfinzi for the treatment of pancreatic cancer opened for enrollment and enrolled first subject March 4, 2024
Onivyde regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA February 26, 2024
US regulatory approval received to start pancreatic cancer Ph IIb trial with nadunolimab February 26, 2024
First Subject Dosed in Ph 1b/2 Study of Ampligen® + Imfinzi for the Treatment of Pancreatic Cancer February 26, 2024
US FDA approval of Onivyde® (Irinotecan Liposome Injection) + NALIRIFOX for 1L mPDAC triggers a $225M milestone payment from Ipsen to Merrimack February 26, 2024
Jazz Pharmaceuticals Enters Definitive Agreement with Redx Pharma to Acquire Global Rights to KRAS Inhibitor Program February 26, 2024
Data from Ph 1b Study of Quemliclustat-Based Regimens Showed Promising OS in Treatment-Naïve Metastatic Pancreatic Cancer January 23, 2024
Enrollment opens for Ph 1b/2 Study of Ampligen® (rintatolimod) + Imfinzi for the Treatment of Pancreatic Cancer January 18, 2024
First Patient Dosed In Ph1/2 Trial Of TNG348 In Patients With BRCA1/2-Mutant and Other HRD+ Cancers January 10, 2024
